Immunogenicity and Safety of Biological E’s Monovalent rDNA Hepatitis B Vaccine (BEVAC®) in Neonates and Infants: A Multicentre, Randomized, Phase IV Non-Inferiority Trial
Authors:
- Subhash ThuluvaSTSubhash Thuluva
- Subbareddy GunneriSGSubbareddy Gunneri
- Siddalingaiah NingaiahSNSiddalingaiah Ningaiah
- Vijay YerrojuVYVijay Yerroju
- Rammohan Reddy MogullaRMRammohan Reddy Mogulla
- Chirag DharCDChirag Dhar
- Kamal ThammireddyKTKamal Thammireddy
- Raju EsanakarraRERaju Esanakarra
- Pradeep NanjappaPNPradeep Nanjappa
- Niranjana S. MahantshettiNMNiranjana S. Mahantshetti
Open Access
Abstract
Biological E’s BEVAC® is a recombinant DNA hepatitis B vaccine that has been used in India for more than a decade in routine early-life immunization and has recently been prequalified by the World Health Organization (WHO). This multicentre, single-blind, parallel-group, randomized phase IV trial, conducted at seven study sites in India, compared the immunogenicity and safety of BEVAC® with a licensed comparator vaccine (GeneVac-B®, Serum Institute of India Pvt. Ltd, Pune, India.) in healthy term neonates and infants. Participants received three 0.5 mL doses administered intramuscularly at birth (within 24 h), 6 weeks of age, and 14 weeks of age. The primary endpoint was seroprotection (anti-HBs IgG ≥10 mIU/mL) at 28 days after the third dose (Day 126), compared using a non-inferiority margin of −10%. Secondary endpoints included safety and tolerability outcomes through Day 126. A total of 468 neonates were randomized (234 per group), of whom 44% were female. At Day 126, seroprotection rates were 98.2% (95% CI: 95.39, 99.50) with BEVAC® and 99.1% (95% CI: 96.78, 99.89) with the comparator; the between-group difference was −0.9% (95% CI: −3.09, 1.24), meeting the prespecified non-inferiority criterion. Solicited adverse events within 7 days after any dose occurred in 29.1% (95% CI: 23.3, 35.3) of BEVAC® recipients and 35.0% (95% CI: 28.9, 41.5) of comparator recipients, most commonly pyrexia, injection-site pain, and swelling; all were mild-to-moderate. No serious adverse events were reported. BEVAC® demonstrated non-inferior immunogenicity to the licensed comparator and a comparable safety profile.Keywords
Funding Information
- Biological E. Limited
This publication has 18 references indexed in Scilit:
- A non-inferiority trial comparing two recombinant vaccines (Hepa-B vs. Engerix-B) for hepatitis B among adults in Dhaka, BangladeshVaccine, 2021
- Hepatitis B vaccination in Indian children: Seroprotection and age-related change in antibody titresMedical Journal Armed Forces India, 2021
- Hepatitis B vaccine birth dose in India: time to reconsiderHuman Vaccines & Immunotherapeutics, 2019
- The immunogenicity of GSK’s recombinant hepatitis B vaccine in children: a systematic review of 30 years of experienceExpert Review of Vaccines, 2017
- Prevention of Perinatal Hepatitis B Virus TransmissionJournal of the Pediatric Infectious Diseases Society, 2014
- Randomized Clinical Trial Comparing Hepatitis B Vaccine Administered by 0, 6 and 14 Week versus 6, 10 and 14 Week Schedule in Healthy InfantsJournal of Tropical Pediatrics, 2009
- Immunogenicity and Reactogenicity of Two Recombinant Hepatitis B Vaccines in Small Infants: A Randomized, Double-Blind Comparative StudyJournal of Tropical Pediatrics, 2007
- Hepatitis B Virus Infection: Epidemiology and VaccinationEpidemiologic Reviews, 2006
- Hepatitis B vaccine – do we need boosters?Journal of Viral Hepatitis, 2003
- Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa IndiansVaccine, 1989